Courtesy Nate Atwater

A Pfizer spinoff has leased nearly 60,000 square feet at Cambridge Crossing, which has now leased 1.3 million square feet to office and lab tenants.

Nervous system disorder specialist Cerevel Therapeutics will fill the last remaining space at 222 Jacobs St., which will be anchored by the new Philips North America headquarters.

Cambridge Crossing developer DivcoWest also has a 504,000-square-foot speculative lab building under construction at 250 Water St.

JLL’s Don Domeretsky and Ben Heller represented Cerevel Therapeutics, which is currently headquartered at 131 Dartmouth St. in Boston.